Back to News
Market Impact: 0.42
IMUNON Highlights 14.7-Month Survival Benefit For IMNN-001; OVATION 3 Enrollment Ahead Of Plan
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
IMUNON reported final Phase 2 results for IMNN-001 in newly diagnosed advanced ovarian cancer showing a 14.7-month median overall-survival advantage versus standard-of-care chemotherapy alone. The company also highlighted continuing enrollment in its pivotal Phase 3 program, supporting a positive clinical-development outlook for the therapy.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.68
Ticker Sentiment
IMNN0.88
More News
- Jensen Huang’s $21 billion net worth in AI rout—Nvidia’s recovery will be ‘capped’ after he admitted affair with alleged Chinese spy
- Nvidia's CEO turmoil gives newly empowered Democrats fresh ammunition in pursuit of oversight
- Paraguay raids ex-president’s home: Why a bank crash brought down Pena
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
- Musk says Tesla will refund some Cybertruck deposits, defends decision to end production
- Weekend trading of Nvidia scandal shines light on new financial products